Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SEP-479 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose | EXPERIMENTAL | - |
| Multiple Ascending Dose | EXPERIMENTAL | - |
| Food Effect | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SEP-479 | DRUG | Oral, capsule |
| Placebo | OTHER | Oral, capsule |
Inclusion Criteria: 1. Subjects who are able and willing to provide informed consent 2. Aged 21 to 60 years at the time of consent 3. Have a BMI within the range 18.0 to 32.0 kg/m2 4. In general good health Exclusion Criteria: 1. Any condition, which in the investigator's opinion might jeopardize...
SEP-479 is an investigational small molecule drug being developed by Septerna, Inc. It is currently in Phase 1 clinical development and is being studied in healthy adult volunteers. Its therapeutic indications have not been disclosed.
SEP-479 targets PTH1R, the parathyroid hormone 1 receptor, which is a G protein-coupled receptor (GPCR). It is a small molecule designed to act on this receptor. Targeting PTH1R places SEP-479 in the GPCR-targeted class of therapeutics.
SEP-479 is being developed by Septerna, Inc., a biotechnology company that trades under the ticker symbol SEPN. Septerna is the sponsor of the clinical program evaluating SEP-479.
SEP-479 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 study is evaluating single and multiple doses in healthy adult participants.
SEP-479 is being evaluated in one active clinical trial, NCT07433179, titled A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants. The trial is currently recruiting, is randomized, double-blind, and controlled, and plans to enroll 150 participants in Australia.